FI | EN


Idylla™ ctKRAS Mutation Assay

2017-01-04 10:06:10

Using liquid biopsies is minimally invasive, fast and easy to perform and provides an excellent solution to study the presence of KRAS mutations in different cancer types like colorectal cancer, pancreatic cancer and non-small cell lung cancer (NSCLC).

Discover the benefits of the Idylla™ ctKRAS Mutation Assay - the easiest solution to implement liquid biopsy testing in your research.

 Highly standardized

 The Idylla™ ctKRAS Mutation Assay, performed on the Biocartis Idylla™ System, is an assay for the qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS gene. The Idylla™ ctKRAS Mutation Assay extracts and amplifies KRAS circulating tumor DNA (ctDNA) from 1 ml of plasma. The Assay is a sample-to-result real-time PCR, intended to use for research applications only.

Idylla™ ctKRAS Mutation Assay Downloads

https://media.biocartis.com/biocartis/documents/TECH_FICHE-ctKRAS-RUO-01122016.pdf

https://media.biocartis.com/biocartis/documents/122076_BRO_Onocolgy.pdf

Contact!
Miika Palviainen
Product Manager
Tel: +358 50 587 5030
miika.palviainen@algol.fi